Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 861 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer July 2, 2024 Hospital Mistakenly Gave Woman a Mastectomy, Then Postponed Her Reconstruction for... July 12, 2021 What Survivors Should Know When Transitioning From Cancer Care to Primary... April 4, 2023 Garbage Men Finally Meet Cancer-Free Toddler After Bonding From Afar August 7, 2019 Load more HOT NEWS Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs Cancer Survivors Face High Rates of Housing Insecurity Radiation-Induced ‘Genomic Scars’ Associate with Poor Patient Outcome A Lack of Resistance Gene Alterations in Baseline ctDNA Associated with...
